DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.35 per share a year ago.
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.